Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Acumen Pharmaceuticals reported an equity compensation grant linked to director Dr. Laura Stoppel, as reflected on this Form 4 by RA Capital entities and related reporting persons. Dr. Stoppel received a restricted stock unit award covering 35,500 shares of common stock and a stock option for 53,250 shares with a $2.29 exercise price.
The RSUs and option will each vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, assuming Dr. Stoppel continues in service through that date. Under her arrangement with RA Capital Management, L.P., she holds these awards for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and must deliver any net stock or cash received to the adviser to offset advisory fees. The reporting persons disclaim beneficial ownership of these awards and the underlying common stock beyond any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.
Role
null | null | null | null | null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 53,250 | $0.00 | -- |
| Grant/Award | Common Stock | 35,500 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 53,250 shares (Indirect, See Footnotes);
Common Stock — 48,300 shares (Indirect, See footnotes)
Footnotes (1)
- Represents a restricted stock unit ("RSU") award to Laura Stoppel. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service through such vesting date. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Under Dr. Stoppel's arrangement with the Adviser, Dr. Stoppel holds the RSUs and the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs, the option and the underlying common stock. Held directly by the Fund. Held directly by the Nexus Fund II. Held directly by the Account. Represents the award of an option to Dr. Stoppel. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to Dr. Stoppel's continuous service through such vesting date.
Key Figures
RSU award size: 35,500 shares
Option shares: 53,250 shares
Option exercise price: $2.29 per share
+5 more
8 metrics
RSU award size
35,500 shares
Restricted stock units granted to Dr. Stoppel
Option shares
53,250 shares
Stock option granted to Dr. Stoppel
Option exercise price
$2.29 per share
Conversion or exercise price for option
Option expiration
June 3, 2036
Expiration date of stock option
RSU-related holdings after grant
48,300 shares
Total shares following RSU transaction entry
Fund holding example
588,850 shares
Indirect common stock holding with footnote-held entity
Fund holding example
1,300,034 shares
Indirect common stock holding with footnote-held entity
Fund holding example
19,103,785 shares
Indirect common stock holding with footnote-held entity
Key Terms
restricted stock unit ("RSU"), investment manager, separately managed account, pecuniary interest, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award to Laura Stoppel."
investment manager financial
"RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P."
separately managed account financial
"RA Capital Management, L.P. is the investment manager for the Fund, the Nexus Fund II and a separately managed account (the "Account")."
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
pecuniary interest financial
"Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaims beneficial ownership ... except to the extent of its or his respective pecuniary interest therein."
advisory fees financial
"Net cash or stock received upon exercise or settlement will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser."
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
FAQ
What equity awards were reported for Acumen (ABOS) director Laura Stoppel?
Dr. Laura Stoppel received a 35,500-share restricted stock unit award and a stock option for 53,250 shares of Acumen common stock at a $2.29 exercise price, both reported indirectly through RA Capital-related reporting persons.
How do the RSUs for Acumen (ABOS) reported by RA Capital vest?
The 35,500 restricted stock units vest in full on the earlier of the first anniversary of the grant date or Acumen’s 2027 annual stockholder meeting, provided Dr. Stoppel maintains continuous service through that vesting date under the described arrangement.
What are the key terms of the Acumen (ABOS) stock option granted to Dr. Stoppel?
The option covers 53,250 shares of Acumen common stock at a $2.29 exercise price and will vest in full on the earlier of the first anniversary of grant or the 2027 annual stockholder meeting, subject to Dr. Stoppel’s continuous service, and expires in 2036.
Who ultimately benefits from the Acumen (ABOS) equity awards granted to Dr. Stoppel?
Under her arrangement with RA Capital Management, Dr. Stoppel holds the RSUs and option for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, turning over net stock or cash received to offset advisory fees owed to the adviser.
Do RA Capital entities claim beneficial ownership of the reported Acumen (ABOS) securities?
RA Capital Management, its general partner, RA Capital Healthcare Fund, RA Capital Nexus Fund II, Dr. Peter Kolchinsky, and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities, including the RSUs, option, and underlying common stock, except to the extent of any pecuniary interest.